Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Journal Article (Journal Article)

Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.

Full Text

Duke Authors

Cited Authors

  • Lee, BD; Shin, J-H; VanKampen, J; Petrucelli, L; West, AB; Ko, HS; Lee, Y-I; Maguire-Zeiss, KA; Bowers, WJ; Federoff, HJ; Dawson, VL; Dawson, TM

Published Date

  • September 2010

Published In

Volume / Issue

  • 16 / 9

Start / End Page

  • 998 - 1000

PubMed ID

  • 20729864

Pubmed Central ID

  • PMC2935926

Electronic International Standard Serial Number (EISSN)

  • 1546-170X

Digital Object Identifier (DOI)

  • 10.1038/nm.2199


  • eng

Conference Location

  • United States